Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Kranenbarg, E.K.; Hamdy, N.A.T.; Putter, H.; ... ; Dutch Breast Canc Res Grp BOOG (2014)

Article / Letter to editor

• neoadjuvant chemotherapy
• zoledronic acid
• bisphosphonates
• menopausal status

• All authors: Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Kranenbarg, E.K.; Hamdy, N.A.T.; Putter, H.; Heijns, J.B.; Warmerdam, L.J.C. van; Kessels, L.; Dercksen, M.; Pepels, M.J.; Maartense, E.; Laarhoven, H.W.M. van; Vriens, B.; Wasser, M.N.; Leeuwen-Stok, A.E. van; Liefers, G.J.; Velde, C.J.H. van de; Nortier, J.W.R.; Kroep, J.R.; Dutch Breast Canc Res Grp BOOG
• Date: 2014-05-31
• Journal: Annals of Oncology
• Volume: 25
• Issue: 5
• Pages: 998 - 1004
• DOI: doi:10.1093/annonc/mdu102